See the DrugPatentWatch profile for bydureon
When does Bydureon's patent expire?
Bydureon's primary patent, U.S. Patent No. 7,750,156, is set to expire on March 18, 2026 [1]. However, the landscape of patent protection for Bydureon is complex, involving multiple patents and potential challenges [1].
What challenges are being faced by Bydureon's patent?
Bydureon is subject to patent litigation, with challenges from generic manufacturers. The U.S. Patent and Trademark Office (USPTO) has issued various rulings concerning the validity of Bydureon's patents. For instance, the USPTO has previously found certain claims of U.S. Patent No. 7,750,156 to be unpatentable [2]. These challenges can impact the drug's market exclusivity and the timeline for generic competition.
Who manufactures Bydureon?
Bydureon is manufactured by Amylin Pharmaceuticals, which is a subsidiary of Bristol-Myers Squibb [3].
What is Bydureon used for?
Bydureon is a medication used for the treatment of type 2 diabetes [4]. It is a long-acting injectable form of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist [4]. It works by improving blood sugar control [4].
How does Bydureon work in the body?
Bydureon is administered weekly and releases exenatide over a prolonged period. Exenatide mimics the action of incretin hormones, which are naturally produced in the body. These hormones stimulate insulin secretion, reduce glucagon secretion, slow gastric emptying, and promote satiety, all of which contribute to lowering blood glucose levels [4].
What are the potential side effects of Bydureon?
Common side effects of Bydureon can include nausea, vomiting, diarrhea, and injection site reactions such as redness, itching, or swelling [4]. More serious side effects, though less common, can include pancreatitis and thyroid C-cell tumors [4].
How is Bydureon administered?
Bydureon is administered as a subcutaneous injection, typically once a week [4]. It is available in both single-dose vial and pre-filled pen formats [4].
What is the difference between Bydureon and other diabetes medications?
As a GLP-1 receptor agonist, Bydureon differs from other classes of diabetes medications such as metformin (a biguanide), sulfonylureas, or insulin. GLP-1 receptor agonists like Bydureon offer benefits such as weight loss and a low risk of hypoglycemia when used alone, which are not always present with other diabetes treatments [4].
Sources:
[1] DrugPatentWatch.com: https://drugpatentwatch.com/
[2] U.S. Patent and Trademark Office (USPTO) filings related to Bydureon patents.
[3] Company reports and press releases from Bristol-Myers Squibb and Amylin Pharmaceuticals.
[4] Prescribing information for Bydureon.